Author

L. Mateu

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Research Focus:host-pathogen & immune response· 2 Research Focus:drug response / drug discovery· 1 Assay:flow cytometry· 1

Frequent Co-Authors

B. Clotet· 3 shared J. Blanco· 3 shared J. Carrillo· 3 shared R. Paredes· 3 shared A. Chamorro· 2 shared A. Valencia· 2 shared I. Blanco· 2 shared J. Rodon· 2 shared

Activity by Year

2020-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

B. Clotet

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Highly functional Cellular Immunity in SARS-CoV-2 Non-Seroconvertors is associated with immune protection

A. Kilpelainen, E. Jimenez-Moyano, O. Blanch-Lombarte, D. Ouchi, R. Penya, B. Quirant-Sanchez, A. Chamorro, I. Blanco, E. Martinez-Caceres, R. Paredes, L. Mateu, J. Carrillo, J. Blanco, C. Brander, M. Massanella, , J. G Prado

The paper examines T-cell immunity in SARS-CoV-2 non-seroconvertors, finding high functional T-cell responses and low immune activation correlate with protection from severe disease without seroconversion.

bioRxiv · May 4, 2021 · PreprintImmunology

Stable neutralizing antibody levels six months after mild and severe COVID-19 episode

E. Pradenas, B. Trinite, V. Urrea, S. Marfil, C. Avila-Nieto, M. L. Rodriguez de la Concepcion, F. Tarres-Freixas, S. Perez-Yanes, C. Rovirosa, E. Ainsua-Enrich, J. Rodon, J. Vergara-Alert, J. Sagales, V. Guallar, A. Valencia, , J. Blanco

This study tracks neutralizing antibody levels in COVID-19 patients up to six months post-infection, finding persistent activity in mild cases and a slower decline in hospitalized individuals.

bioRxiv · Nov 22, 2020Immunology

Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect after a Drug Repurposing Screen

J. Rodon, J. Munoz-Basagoiti, D. Perez-Zsolt, M. Noguera-Julian, R. Paredes, L. Mateu, C. Quinones, I. Erkizia, I. Blanco, A. Valencia, V. Guallar, J. Carrillo, J. Blanco, J. Segales, B. Clotet, , N. Izquierdo-Useros

This study screens existing drugs to identify potent inhibitors of SARS-CoV-2-induced cytopathic effect and viral replication, finding plitidepsin as the most effective clinically approved drug.

bioRxiv · Apr 23, 2020 · PreprintMicrobiology